# IBDAI - Inflammatory Bowel Disease Management Platform
## Venture Specification

**Date:** 2026-03-02
**Category:** Healthcare AI / Gastroenterology
**Status:** GO - Pursue
**Score:** 8.21/10

---

## Executive Summary

IBDAI is an AI-powered platform for gastroenterologists that automates IBD endoscopic scoring (SES-CD, Mayo Score), disease activity assessment, biologic response prediction, mucosal healing assessment, and flare management. The platform addresses a critical need in inflammatory bowel disease care where 1.7M Americans suffer from Crohn's disease and ulcerative colitis, and treatment decisions involving $50K+ annual biologic therapies depend on subjective endoscopic assessments.

**Key Metrics:**
- Total Addressable Market: 12,000+ US gastroenterologists
- Patient Population: 1.7M IBD patients (800K Crohn's, 900K UC)
- Annual Biologic Spend: $85B+ (US alone)
- Target CAC: $300
- Target LTV: $72,000
- Gross Margin: 85%

---

## 1. Problem Statement

### Clinical Pain Points

**Endoscopic Scoring Subjectivity**
- SES-CD (Simple Endoscopic Score for Crohn's Disease) scoring varies significantly between observers
- Mayo Score for ulcerative colitis requires expert training
- Scoring takes 15-30 minutes per procedure
- No standardized real-time assessment during endoscopy

**Biologic Therapy Challenges**
- Annual cost: $50,000+ per patient
- 30-40% primary non-response rate
- 20-30% secondary loss of response annually
- Prior authorization delays: 2-4 weeks average
- No reliable prediction of which biologic will work for which patient

**Mucosal Healing Assessment**
- Gold standard treatment target (STRIDE-II guidelines)
- Requires expert review of endoscopic images/video
- Often assessed retrospectively, delaying treatment decisions
- Inter-observer agreement: kappa 0.4-0.6 (moderate at best)

**Disease Flare Management**
- Flares unpredictable, leading to emergency visits
- Hospitalization costs: $15,000+ per admission
- No reliable early warning system
- Patient-reported symptoms correlate poorly with inflammation

### Economic Impact

| Cost Category | Annual Impact (US) |
|--------------|-------------------|
| Biologic therapies | $85+ billion |
| IBD hospitalizations | $3-5 billion |
| Emergency visits | $1-2 billion |
| Endoscopic procedures | $2-3 billion |
| Lost productivity | $6-8 billion |
| **Total** | **$97-103 billion** |

---

## 2. Solution Overview

### Core AI Capabilities

**1. Endoscopic Scoring Automation**
- Real-time SES-CD scoring during colonoscopy
- Mayo Score calculation for ulcerative colitis
- Segment-by-segment inflammation quantification
- Automated detection of ulcers, erosions, strictures

**2. Mucosal Healing Assessment**
- Computer vision analysis of colonoscopy video
- Objective mucosal healing quantification
- Historical comparison (baseline vs. current)
- Healing trajectory prediction

**3. Biologic Response Prediction**
- Primary response likelihood by drug class
- Secondary failure risk assessment
- Biomarker integration (fecal calprotectin, CRP)
- Pharmacogenomic considerations

**4. Disease Activity Monitoring**
- Multi-modal data fusion (endoscopy + biomarkers + symptoms)
- Activity score calculation (HBI, PMS)
- Flare risk prediction
- Treatment optimization recommendations

**5. Prior Authorization Support**
- Automated documentation generation
- Medical necessity justification
- Clinical trial citation support
- Appeals letter assistance

### Product Tiers

| Feature | Starter | Professional | Enterprise |
|---------|---------|--------------|------------|
| Endoscopic Scoring | SES-CD only | Full suite | Full suite |
| Mucosal Healing | Basic | Advanced + tracking | Research-validated |
| Biologic Prediction | None | Drug class | Drug-specific |
| Flare Prediction | None | Basic | Advanced |
| Prior Auth Support | Templates | Full automation | Full + appeals |
| EHR Integration | None | Basic | Deep integration |
| Research Tools | None | None | Included |
| Multi-center | No | No | Yes |
| Monthly Price | $1,500 | $2,000 | $4,000 |

---

## 3. Market Analysis

### Target Customer Segments

**Primary: Gastroenterologists**
- IBD specialists (3,000 US)
- General gastroenterologists with IBD focus (6,000 US)
- IBD center directors and fellows (3,000 US)

**Secondary: Institutional**
- IBD centers of excellence (~200 US)
- Academic medical centers with IBD programs
- Community gastroenterology practices

**Tertiary: Industry Partners**
- Biologic manufacturers (J&J, AbbVie, Pfizer, Takeda)
- Endoscopy equipment manufacturers
- Health insurance companies

### Market Sizing

**Total Addressable Market (TAM)**
- 12,000 US gastroenterologists × $24,000/year = $288M

**Serviceable Addressable Market (SAM)**
- IBD-focused gastroenterologists (6,000) × $24,000/year = $144M

**Serviceable Obtainable Market (SOM)**
- 3% market share in Year 3 = 180 practices × $24,000/year = $4.3M ARR

### Competitive Landscape

**Direct Competitors:**
| Company | Product | Strength | Weakness |
|---------|---------|----------|----------|
| Olympus | EndoAI | OEM integration | General GI, not IBD-specific |
| Fujifilm | CAD EYE | Installed base | Limited scoring capability |
| Medtronic | GI Genius | Broad GI focus | No biologic prediction |
| Iterative Scopes | Skout | Polyp focus | Not IBD-focused |

**Indirect Competitors:**
- IBD-specific EHR modules (proVation, gMed)
- Biomarker testing companies (LabCorp, Quest)
- Clinical decision support tools (UpToDate, MKSAP)

**Differentiation:**
Only AI platform dedicated to IBD with endoscopic scoring + mucosal healing + biologic response prediction in one integrated suite.

---

## 4. Why Now

### Market Catalysts

**1. Rising IBD Prevalence**
- Western diet and environmental factors driving increase
- 3% annual growth in IBD diagnoses
- Earlier onset in new generations

**2. Biologic Revolution**
- 15+ FDA-approved biologics for IBD
- Biosimilars increasing access but adding complexity
- Precision medicine becoming standard of care

**3. Guideline Evolution**
- STRIDE-II guidelines emphasize mucosal healing
- Treat-to-target approach widely adopted
- Value-based care pressure

**4. AI Maturity**
- Computer vision for endoscopy validated
- GPU costs declining
- Regulatory pathways clearer (FDA SaMD)

**5. Payment Reform**
- Prior authorization burdens increasing
- Bundled payments for IBD care
- Quality metrics tied to reimbursement

### Timing Indicators

| Signal | Status |
|--------|--------|
| IBD prevalence rising | Accelerating |
| Biologic approvals | 3-5 new/year expected |
| AI FDA approvals | 10+ GI AI devices cleared |
| Prior auth burden | Increasing 15% YoY |
| IBD center consolidation | Accelerating |

---

## 5. AI Advantage

### Technical Capabilities

**Endoscopic Video Analysis**
```
Input: Colonoscopy video stream (1080p, 30fps)
Processing: Real-time frame analysis
CNN Architecture: ResNet-50 + Temporal LSTM
Output: SES-CD score by segment, ulcer detection, inflammation grading
Accuracy Target: >0.85 Cohen's kappa vs. expert consensus
Latency: <500ms from frame to prediction
```

**Mucosal Healing Quantification**
```
Input: Historical + current endoscopy
Analysis: Multi-scale texture analysis
Metrics: Vascular pattern, ulceration, erosions
Output: Healing score (0-100), trajectory, prediction
Confidence: 95% CI provided
```

**Biologic Response Prediction**
```
Features: Endoscopic severity + biomarkers + genetics + prior response
Model: Gradient boosting + neural network ensemble
Training: Multi-center retrospective cohorts
Output: Response probability by drug class
Calibration: Brier score <0.2
```

**Flare Risk Prediction**
```
Inputs: Symptom diary + calprotectin trend + medication adherence
Model: Survival analysis (time-to-flare)
Output: 30/60/90-day flare probability
Action threshold: >20% risk = alert
```

### Data Strategy

**Training Data Requirements:**
- 50,000+ annotated endoscopic videos
- 10,000+ patient outcome trajectories
- 5,000+ biologic response pairs
- Multi-center diversity (10+ institutions)

**Data Partnerships:**
- Academic IBD centers (research agreements)
- Endoscopy video de-identification services
- Biologic manufacturers (clinical trial data)
- Patient registry partnerships

---

## 6. Viral Mechanism

### Conference Strategy

**Primary Conferences:**
- DDW (Digestive Disease Week): 15,000+ attendees
- IOIBD (International Organization for IBD): 1,500 specialists
- ACG (American College of Gastroenterology): 5,000+ attendees
- AGA (American Gastroenterological Association): 4,000+ attendees
- Advances in IBD: 2,000+ IBD-focused clinicians

**Viral Content Hooks:**
1. "This AI predicted biologic failure 3 months before clinician" - Case study videos
2. "AI catches mucosal inflammation humans missed" - Side-by-side comparisons
3. "50% reduction in scoring time with better accuracy" - ROI demonstrations
4. "Prevented 12 hospitalizations in 6 months" - Outcomes data

**Referral Loops:**
- IBD center directors → Referring gastroenterologists
- Academic IBD programs → Community practices
- Fellowship programs → New graduates

### Thought Leadership

**Content Strategy:**
- Monthly IBD AI webinars (CME credit)
- Case study library with video demonstrations
- Peer-reviewed publications (IBD journals)
- Podcast appearances (IBD-focused shows)

---

## 7. Revenue Model

### Pricing Structure

**Per-Practice Subscription:**

| Tier | Monthly | Annual | Included Patients | Additional Patient |
|------|---------|--------|-------------------|-------------------|
| Starter | $1,500 | $15,000 | 50 | $30/year |
| Professional | $2,000 | $20,000 | 100 | $25/year |
| Enterprise | $4,000 | $40,000 | 500 | $20/year |

**Add-on Services:**
- Prior Auth Automation: +$500/month
- Research Portal: +$1,000/month
- Multi-site Consolidation: +$1,500/month
- API Access: +$2,000/month

### Unit Economics

**Customer Acquisition Cost (CAC):**
- DDW conference booth + leads: $15,000 / 50 leads = $300/lead
- Webinar + content marketing: $100/lead
- Referral program: $50/lead
- Blended CAC: $200-300

**Lifetime Value (LTV):**
- Average subscription: $24,000/year
- Retention: 36 months (switching costs high)
- Expansion: 20% annual upsell
- LTV: $72,000+

**Gross Margin:**
- Infrastructure (AWS HIPAA): 10%
- Support: 3%
- Customer success: 2%
- **Gross Margin: 85%**

**Payback Period:**
- CAC: $300
- Monthly contribution: $1,700 (85% of $2,000)
- Payback: <2 months

### Revenue Projections

**Year 1: Launch**
- 12 practices acquired (1/month average)
- ARPU: $2,000
- MRR: $24,000
- ARR: $288,000

**Year 2: Growth**
- 60 total practices (48 new)
- Expansion to 25% Professional tier
- MRR: $120,000
- ARR: $1.44M

**Year 3: Scale**
- 180 total practices (120 new)
- Enterprise tier launches (20% of base)
- MRR: $360,000
- ARR: $4.32M

---

## 8. MVP in 8 Weeks

### Development Plan

**Weeks 1-2: Foundation & Data**
- Partner with one IBD center for data access
- Set up HIPAA-compliant infrastructure
- Collect 500+ annotated endoscopic videos
- Define annotation schema (SES-CD segments)
- Establish IRB protocol for pilot

**Deliverables:**
- Data sharing agreement signed
- Infrastructure deployed
- 50 videos annotated
- Annotation schema validated

**Weeks 3-5: Core AI Model**
- Build SES-CD scoring CNN
- Train on annotated dataset
- Validate against expert scores
- Implement ulcer detection
- Build basic API

**Deliverables:**
- SES-CD model >0.85 agreement
- Ulcer detection F1 >0.80
- API endpoint functional
- Validation report

**Weeks 6-7: Pilot Integration**
- Deploy to pilot IBD center
- Real-time scoring during procedures
- Collect feedback from 3 gastroenterologists
- Compare scoring time (before vs. after)
- Refine model based on feedback

**Deliverables:**
- Pilot deployment complete
- 20+ procedures scored
- Feedback documented
- Model refined

**Week 8: Demo & Validation**
- Prepare DDW conference demo
- Create marketing materials
- Analyze pilot results
- Secure pilot commitment for expansion

**Deliverables:**
- Demo ready for DDW
- Pilot validation report
- One practice commits to paid pilot
- Series of case studies

### MVP Validation Metrics

**Technical Validation:**
- SES-CD scoring: >0.85 Cohen's kappa vs. expert
- Ulcer detection: >0.80 F1 score
- Processing time: <500ms per frame
- System uptime: >99%

**Clinical Validation:**
- Scoring time reduction: >50%
- Inter-observer agreement: Improved by >30%
- Physician satisfaction: >4/5 NPS

**Commercial Validation:**
- One IBD center commits post-pilot
- Two additional centers express interest
- CAC validated <$400

---

## 9. Tech Stack

### Architecture Overview

```
┌─────────────────────────────────────────────────────────┐
│                    Frontend Layer                       │
│  React/Next.js + TypeScript + Tailwind CSS             │
│  Real-time video display + Scoring dashboard           │
└─────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────┐
│                    API Layer                            │
│  Python/FastAPI + Redis cache + Rate limiting          │
│  /score-ses-cd  /predict-biologic  /assess-healing    │
└─────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────┐
│                    AI Services                          │
│  PyTorch + ONNX Runtime                                │
│  SES-CD Model  │  Mucosal Healing  │  Biologic Response│
│  (CNN+LSTM)    │  (CNN ResNet50)   │  (XGBoost)        │
└─────────────────────────────────────────────────────────┘
                            ↓
┌─────────────────────────────────────────────────────────┐
│                  Data Layer                             │
│  PostgreSQL (metadata)  │  S3 (video storage)          │
│  Redis (cache)          │  Elastic (search)            │
└─────────────────────────────────────────────────────────┘
```

### Technology Choices

**Backend:**
- Python 3.11+
- FastAPI (async, type-safe, fast)
- Pydantic (validation)
- Celery (background tasks)

**AI/ML:**
- PyTorch 2.0+ (training)
- ONNX Runtime (inference)
- Scikit-learn (traditional ML)
- OpenCV (video processing)
- MONAI (medical imaging)

**Integrations:**
- Endoscopy systems: DICOM, HL7 FHIR
- EHR: Epic, Cerner (FHIR API)
- Prior auth: CoverMyMeds, Surescripts

**Infrastructure:**
- AWS us-east-1 (HIPAA compliant)
- ECS/Fargate (containers)
- S3 with KMS (video storage)
- RDS PostgreSQL (metadata)
- VPC isolated (HIPAA)

**Monitoring:**
- DataDog (infrastructure)
- Weights & Biases (ML experiments)
- Sentry (error tracking)

### Security & Compliance

**HIPAA Compliance:**
- BAA with all vendors
- Encryption at rest (AES-256)
- Encryption in transit (TLS 1.3)
- Access logging (all PHI access)
- Minimum necessary PHI handling

**SOC 2 Type II:**
- Target certification within 18 months
- Automated compliance monitoring
- Annual third-party audit

**FDA:**
- SaMD (Software as Medical Device) pathway
- 510(k) or de novo classification
- Clinical validation study design

---

## 10. Risk Factors

### Technical Risks

**1. Endoscopic Video Data Access**
- Risk: Proprietary systems, hospital IT barriers
- Mitigation: OEM partnerships, research agreements, SaaS delivery

**2. Scoring Subjectivity**
- Risk: Expert disagreement on "ground truth"
- Mitigation: Consensus annotation, expert panel, uncertainty quantification

**3. Model Generalization**
- Risk: Model trained on one center doesn't transfer
- Mitigation: Multi-center training, domain adaptation, continuous learning

### Commercial Risks

**4. Biologic Prediction Liability**
- Risk: Wrong prediction leads to disease progression
- Mitigation: Clear disclaimers, decision support (not decision making), liability insurance

**5. Endoscopy OEM Competition**
- Risk: Olympus, Fujifilm build similar features
- Mitigation: OEM-agnostic, faster innovation, IBD-specialization

**6. EHR Integration Complexity**
- Risk: Integration costs and delays
- Mitigation: FHIR standards, phased integration, API-first design

### Market Risks

**7. Reimbursement Uncertainty**
- Risk: No CPT code for AI-assisted scoring
- Mitigation: Cost savings ROI, value-based care arrangements

**8. Adoption Barriers**
- Risk: Physician resistance to AI recommendations
- Mitigation: Augmented intelligence (not replacement), early adopter KOLs

**9. Regulatory Delays**
- Risk: FDA clearance takes longer than expected
- Mitigation: Clinical study preparation, regulatory counsel, PMA pathway parallel

### Risk Matrix

| Risk | Probability | Impact | Mitigation Priority |
|------|-------------|--------|---------------------|
| OEM competition | High | High | High |
| Data access | Medium | High | High |
| Liability | Low | High | Medium |
| Regulatory delay | Medium | Medium | Medium |
| Adoption | Medium | Medium | Low |

---

## 11. Competitive Threat Analysis

### Endoscopy Manufacturers

**Olympus (EndoAI)**
- Strength: Installed base, OEM integration
- Weakness: General GI focus, not IBD-specific
- Threat Level: High
- Counter: Faster innovation, IBD specialization

**Fujifilm (CAD EYE)**
- Strength: AI maturity, partnership ecosystem
- Weakness: Limited scoring capabilities
- Threat Level: Medium
- Counter: Biologic prediction differentiation

**Medtronic (GI Genius)**
- Strength: Broad GI AI portfolio
- Weakness: Modular add-on, not integrated IBD suite
- Threat Level: Medium
- Counter: Deep IBD workflow integration

### Emerging Threats

**Hospital-built Solutions**
- Mayo Clinic, Cleveland Clinic, Mount Sinai
- Strength: Data access, clinical validation
- Weakness: Slow development, limited commercialization
- Threat Level: Low (near term), Medium (long term)

**Big Tech Entry**
- Google Health, Microsoft Healthcare
- Strength: AI talent, infrastructure
- Weakness: Lack of healthcare focus, regulatory unfamiliarity
- Threat Level: Low (near term)

**Moat Strategy:**
1. Data network effects (more procedures = better model)
2. Workflow integration (sticky once adopted)
3. IBD specialization (hard for general AI to replicate)
4. KOL relationships (IBD community tight-knit)

---

## 12. Go/No-Go Decision

### Decision: GO - Pursue

**Score: 8.21/10**

### Strengths Supporting GO

**1. Market Size**
- 1.7M IBD patients in US
- 12,000 gastroenterologists
- $85B+ annual biologic spend
- Growing 3-5% annually

**2. Clinical Urgency**
- Biologics: $50K+ annual cost per patient
- High non-response rates (30-40%)
- Subjective scoring drives treatment decisions
- Mucosal healing = treatment target

**3. AI Native Application**
- Endoscopic CV is AI-native
- Computer vision mature for this use case
- Multi-modal AI (video + biomarkers + outcomes)

**4. Proven Pattern**
- Prior authorization automation (8.4+ score achieved)
- Credential + regulatory pattern (gastroenterology + FDA)
- B2B SaaS to specialists (validated model)

**5. Viral Potential**
- "AI predicted biologic failure" = compelling case study
- DDW/IOIBD conferences = concentrated IBD community
- IBD centers refer to each other

### Weaknesses to Address

**1. Data Access Challenge**
- Endoscopic video = proprietary formats
- Solution: OEM partnerships, research agreements, SaaS delivery

**2. OEM Competition**
- Risk of being "Sherlocked"
- Solution: Move faster, IBD specialization, multi-OEM support

**3. Expert Disagreement**
- Scoring subjectivity = fuzzy ground truth
- Solution: Consensus annotation, uncertainty quantification, expert panel

### Critical Success Factors

**Must Have:**
1. Hire gastroenterologist/IBD specialist as co-founder or advisor
2. Partner with one IBD center for endoscopic video access (Week 1-2)
3. Start with SES-CD scoring (clear ROI, validated endpoint)
4. Add biologic response prediction (key differentiator)
5. Build DDW/IOIBD conference relationships (viral channel)

**Nice to Have:**
1. Biologic manufacturer partnership (funding + data)
2. Multi-center pilot (generalization proof)
3. FDA pathway initiated early (regulatory de-risking)
4. Prior authorization automation (near-term revenue)

---

## 13. Implementation Roadmap

### Phase 1: MVP (Months 1-3)

**Goal: Validated product with paying pilot customers**

- Month 1: Data partnerships, infrastructure, annotation
- Month 2: SES-CD model build, API development
- Month 3: Pilot deployment, validation, refinement

**Milestones:**
- 1 IBD center partnership signed
- 500 annotated videos
- SES-CD model >0.85 agreement
- 3 gastroenterologist pilots
- 1 paying pilot customer

### Phase 2: Product-Market Fit (Months 4-9)

**Goal: 10 paying practices with demonstrated outcomes**

- Months 4-6: Add Mayo scoring, mucosal healing, prior auth
- Months 7-9: Biologic response prediction, EHR integration

**Milestones:**
- 10 paying practices
- $20K MRR
- 5,000 procedures scored
- Clinical outcomes study initiated
- DDW product launch

### Phase 3: Scale (Months 10-18)

**Goal: 50 practices, path to profitability**

- Months 10-12: Enterprise tier, research portal
- Months 13-15: Multi-site customers, API access
- Months 16-18: FDA submission preparation

**Milestones:**
- 50 paying practices
- $100K MRR
- 2 enterprise customers
- FDA 510(k) submitted
- Series A fundraising

---

## 14. Team Requirements

### Core Roles

**Technical:**
- ML Engineer (Computer Vision): Endoscopic video models
- Backend Engineer: API, EHR integration
- Frontend Engineer: Real-time scoring interface
- ML Ops: Model deployment, monitoring

**Clinical:**
- Gastroenterologist (Co-founder or Advisor): IBD expertise
- Nurse Coordinator: Pilot site management, training
- Medical Writer: Documentation, publications

**Business:**
- Sales: IBD practice sales (conference-based)
- Customer Success: Practice onboarding, retention
- Marketing: Content, webinars, conferences

### Advisors Needed

1. **IBD KOL**: Academic IBD center director
2. **GI AI Researcher**: Published in endoscopic AI
3. **FDA Regulatory**: SaMD clearance experience
4. **Healthcare VC**: B2B healthcare SaaS expertise

### Hiring Plan

**Month 1:**
- ML Engineer (founder technical)
- Gastroenterologist advisor (equity)

**Month 3:**
- Backend Engineer (first hire)
- Customer Success (first non-technical)

**Month 6:**
- Frontend Engineer
- Sales (conference focus)

**Month 12:**
- ML Ops
- Marketing (content focus)

---

## 15. Investment Ask

### Seed Round: $2M

**Use of Funds:**

| Category | Amount | Purpose |
|----------|--------|---------|
| Engineering | $1.0M | 4 engineers × 18 months |
| Data | $300K | Annotation, partnerships, storage |
| Sales/Marketing | $300K | Conferences, content, demos |
| Operations | $200K | Legal, insurance, compliance |
| Clinical | $150K | Advisor fees, studies |
| Buffer | $50K | Contingency |

**Milestones to Series A:**
- 50 paying practices
- $100K MRR
- 20,000 procedures scored
- Clinical validation study complete
- FDA submission prepared
- 18-month runway

**Series A Target: $8-10M**
- Scale sales (DDW, ACG, AGA)
- Enterprise features
- FDA clearance
- OEM partnerships

---

## 16. Key Assumptions

### Must Be True

1. **Gastroenterologists want automated scoring** - Willing to pay $1,500-2,000/month
2. **AI can achieve expert-level agreement** - >0.85 kappa is achievable
3. **Practices will share video data** - Data partnerships are feasible
4. **Prior auth automation is valuable** - Practices will pay for this
5. **Biologic prediction is possible** - Predictive signal exists in data

### Should Validate Early

1. **Pricing sensitivity** - Will practices pay >$1,500/month?
2. **Data access friction** - How hard to get endoscopic video?
3. **OEM threat timing** - When will Olympus/Fujifilm compete?
4. **Regulatory timeline** - How long to FDA clearance?
5. **Adoption barriers** - Will gastroenterologists trust AI?

### Assumption Testing Plan

**Month 1:**
- Interview 20 gastroenterologists (pain validation)
- Data access exploration with 5 IBD centers
- Pricing conversations with 10 practice administrators

**Month 2:**
- MVP prototype testing with 3 gastroenterologists
- Willingness-to-pay survey
- OEM partnership conversations

**Month 3:**
- Pilot conversion to paying customer
- Time savings measurement
- Satisfaction scoring

---

## 17. Success Metrics

### North Star Metric

**Procedures Scored per Month**
- Month 3: 100
- Month 6: 1,000
- Month 12: 10,000
- Month 18: 50,000

### Product Metrics

- Activation rate: >70% (deploy to first procedure within 2 weeks)
- Weekly active usage: >80% of deployed practices
- Scoring time reduction: >50% vs. manual
- Physician NPS: >50

### Commercial Metrics

- CAC: <$300
- LTV: >$60,000
- Payback: <3 months
- Net revenue retention: >120%
- Logo retention: >90%

### Clinical Metrics

- SES-CD agreement: >0.85 kappa
- Flare prediction AUC: >0.75
- Biologic response prediction: >0.70 accuracy
- Hospitalization reduction: >20% (monitored practices)

---

## 18. Exit Strategy

### Potential Acquirers

**Strategic Buyers:**
1. **Endoscopy OEMs** - Olympus, Fujifilm, Pentax Medical
2. **EHR Companies** - Epic, Cerner (modernization)
3. **Biologic Manufacturers** - J&J, AbbVie, Pfizer (patient access)
4. **Health Systems** - Large IBD center networks
5. **Radiology AI** - Path AI, Rad AI (adjacent expansion)

**Financial Buyers:**
1. Healthcare-focused PE (TPG, KKR)
2. Growth equity (Insight, TCV, Spectrum)
3. Corporate venture (GV, Salesforce Ventures)

### Exit Timeline

**Target: 5-7 years**

**Pre-exit milestones:**
- $10M+ ARR
- 500+ practices
- FDA clearance
- Published clinical validation
- Multiple OEM partnerships

**Valuation Drivers:**
- Revenue multiple (15-25x SaaS)
- Strategic value (OEM defense)
- Clinical validation (published outcomes)
- Regulatory moat (FDA clearance)

---

## 19. Conclusion

IBDAI represents a compelling AI venture opportunity at the intersection of gastroenterology, computer vision, and precision medicine. The market is large (1.7M patients), growing (3-5% annually), and underserved by current AI solutions (general GI focus only).

**Key Success Factors:**
1. Data access partnerships with IBD centers
2. IBD specialist co-founder/advisor
3. Focus on SES-CD scoring first (clear ROI)
4. Biologic response prediction as differentiator
5. DDW/IOIBD conference community building

**Why This Scores 8.21/10:**
- Largest specialist market in current cycle (12K gastroenterologists)
- High-stakes treatment decisions ($50K+ biologics)
- AI-native application (endoscopic CV)
- Proven pattern match (prior authorization, credential + regulatory)
- Viral potential (biologic failure prediction case studies)

**Final Recommendation: GO**

IBD endoscopic AI + biologic response prediction = precision IBD care. This is the right market, the right problem, the right time, and the right AI application. Execute on the MVP, secure IBD center partnerships, and build the definitive IBD AI platform.

---

*Document Version: 1.0*
*Last Updated: 2026-03-02*
*Status: Approved for Pursuit*
